Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug

A new CSO isn't all Dermavant got from GlaxoSmithKline: The Roivant unit has picked up the rights to the British drugmaker's dermatology drug tapinarof in a deal worth up to £250 million ($330 million). The asset is poised to enter phase 3 in psoriasis and atopic dermatitis and is also in preclinical development in a "back-up" program.